Announcements Trials
Browse Landscape

Status

Available 1Approved for marketing 1

Sponsor Class

OTHER 2

Study Type

Interventional 79Observational 26Expanded_access 2

Sponsor

Cancer Type

Tumor-Agnostic 19CNS 6Sarcoma 5Lymphoid 4Thoracic 2Other hematologic neoplasm 2Gynecologic 2Gastrointestinal 2Endocrine 2Breast 2Other neoplasm 1NET 1Myeloid 1Genitourinary 1Dermatologic 1Classical hematology 1

Conditions

Pheochromocytoma 7Neuroendocrine Tumors 7Paraganglioma 5Neuroblastoma 5Insulinoma 3Carcinoid Tumor 3Recurrence 2Neoplasms 2Hypoglycemia 2Hyperinsulinism 2Carcinoma, Medullary 2Adenoma, Islet Cell 2Thyroid cancer, medullary 1Thyroid Cancer, Papillary 1Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive 1Liposarcoma 1Fibrosarcoma 1Congenital Hyperinsulinism 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Beckwith-Wiedemann Syndrome 1

Interventions

3-Iodobenzylguanidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Expanded_access × Neoplasms × Endocrine × Clear all
NCT07262970 2025-12-04

Intermediate-Size Cohort EAP for Ersodetug in Patients With Inadequately Controlled Hypoglycemia Related to a Tumor

Rezolute

Available
EndocrineNETSarcoma

Fibrosarcoma, Hyperinsulinism, Hypoglycemia, Insulinoma, Adenoma, Islet Cell, Liposarcoma, Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

NCT01377532 2020-05-06

Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma

University of California, San Francisco

Approved for marketing
CNSEndocrine

Neoplasms, Paraganglioma, Pheochromocytoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡